ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 37.9 | 17.0 | 10.4 |
| Total income | 37.9 | 17.0 | 10.4 |
| Profit before exceptional items & tax | 0.7 | 0.3 | 0.1 |
| Profit before tax | 0.7 | 0.3 | 0.1 |
| Net profit | 0.5 | 0.2 | 0.0 |
| Operating margin | 1.8% | 1.8% | 1.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +150.00% |
|---|---|
| Revenue, year on year | +264.40% |
BSE results filing, NSE: CONCORD. Figures extracted from the filing.
Concord Drugs Ltd: key numbers
- Share price
- ₹71.11
- Market cap
- ₹93.69 Cr
- Revenue (annual)
- ₹78.74 Cr
- Net profit (annual)
- ₹1.06 Cr
- P/E (TTM)
- 45.7×Sector 43.8×
- Promoter holding
- 45.08%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Drugs Ltd
All →Concord Drugs Board Meeting Date
Concord Drugs will hold a board meeting on 12 November 2026 to consider September 2026 half-year results. Trading window is closed until 15 November 2026.
Concord Drugs Other Announcement
Concord Drugs Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per SEBI regulations.
Concord Drugs Annual General Meeting
Concord Drugs Limited held its 31st Annual General Meeting on September 30, 2026. The meeting covered adoption of financial statements, director appointments, and auditor re-appointment.
Concord Drugs Other Announcement
Concord Drugs Limited is notifying shareholders about the annual report web-link as per Regulation 36(1)(b). Shareholders are urged to update their email addresses.
Concord Drugs Annual Report
Concord Drugs Limited submitted its 31st Annual Report for FY 2025-26 and notice of the 31st Annual General Meeting scheduled for 30th September 2026.
Concord Drugs Annual General Meeting
Concord Drugs approved the notice for its 31st AGM on September 30, 2026. The board also finalized director re-appointments and set book closure dates.